NCT06615869View on ClinicalTrials.gov

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

February 27, 2023

Study Completion Date

March 15, 2023

Conditions

Healthy

Interventions

DRUG

Molnupiravir

Oral Administration.

Trial Locations (1)

33143

QPS-MRA, LLC-Early Phase (Site 0002), South Miami

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY